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ABSTRACT  
Background: The increase over the past decade in the non-medical use of prescription 
opioids and illicit opioids in North America has resulted in significant health-related 
harms.  
 
Objective: We sought to examine temporal trends and correlates of the availability of 
illicit and prescription opioids among people who inject drugs (PWID) in Vancouver, 
Canada.  
 
Methods: Data were derived from three prospective cohort studies of PWID in 
Vancouver between 2010 and 2014. In semiannual interviews, participants reported the 
availability of five sets of illicit and prescription opioids: (1) heroin; (2) Percocet 
(oxycodone/acetaminophen), Vicodin (hydrocodone/acetaminophen) or Demerol 
(meperidine); (3) Dilaudid (hydromorphone); (4) Morphine; (5) oxycontin/OxyNEO 
(controlled-release oxycodone). We defined perceived availability as immediate (e.g., 
available within 10 minutes) vs. no availability/available after 10 minutes. The trend 
and correlation of immediate availability were identified by multivariable generalized 
estimating equations logistic regression. 
 
Results: Among 1584 participants, of which 564 (35.6%) were female, the immediate 
availability of all illicit and prescribed opioids (except for oxycontin/OxyNEO) 
increased over time, independent of potential confounders. The Adjusted Odds Ratios 
of immediate availability associated with every calendar year increase were between 
1.09 (95% confidence interval 1.05-1.12) (morphine and Dilaudid) and 1.13 (95% 
confidence interval 1.09-1.17) (Percocet/Vicodin/Demerol) (all p-values <0.05).  
 
Conclusion: The availability of most prescription opioids had continued to increase in 
recent years among our sample of PWID in Vancouver. Concurrent increases in the 
availability of heroin were also observed, raising concerns regarding combination of 
both illicit and prescription opioids use among PWID that could potentially increase the 
risk of overdose.  
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INTRODUCTION 
While opioids have been an invaluable tool for pain management in clinical 
settings, the rising trend in the non-medical use of prescription opioids has become a 
national epidemic with both economic and healthcare implications (1). In 2012, the 
National Survey of Drug Use and Health estimated that 2.1 million people in the United 
States had a substance-use disorder related to prescription opioids, compared to 467,000 
with a substance use disorder related to heroin (2). More recently, a study demonstrated 
a 200% increase in rates of death related to opioid overdose since 2000 and the age-
adjusted rate of death involving synthetic opioids (other than methadone) increased by 
80% between 2013 and 2014 alone (3). Similar trends in illicit and prescription opioid 
use have been observed in Canada. Non-medical prescription opioids use in Canada 
increased by 70% between 2009 and 2014 (4). Opioid related death, with more than 90% 
accounted for by prescription opioids use, increased by three-fold between 2006 and 
2011 in Ontario, Canada (5). Despite several strategies such as prescription monitoring 
program adopted by the provincial ministry to improve opioid prescribing, the rate of 
high-dose opioid dispensing increased by 23% between 2006 and 2011 (6). Increases in 
non-medical prescription opioids availability and use have also been observed among 
people who use illicit drugs. Specifically, a 24% increase in non-medical prescription 
opioids use was observed among people who use illicit drugs in Canada between 2002 
and 2005 (7).  
A previous study in Vancouver, Canada showed an increase in availability of 
prescription opioids from 2006-2010 among street-involved people who use drugs while 
availability of other more traditional drugs of abuse such as heroin and crack remained 
stable during the same period (8). However, beyond 2010, little is known regarding 
recent trends in illicit and prescription opioid availability among this population 
despite accumulating evidence suggesting rising trends in both illicit and prescription 
opioid use in the general population (3, 9, 10).  In fact, in response to increase in drug 
related overdose in British Columbia, the province’s senior public health official 
declared a public health emergency in April 2016 (11). 
Recent US studies have indicated a shifting pattern of prescription opioids and 
heroin use. Cicero, Ellis (12) found an annual increase of 10.3% in concurrent heroin use 
with prescription opioids use between 2008 and 2014 despite a steady annual decrease 
of 6.3% in prescription opioids use, suggesting that prescription opioids users were 
transitioning to heroin use. However, the factors contributing to the transition were not 
clearly established in the study except that 73% of respondents in a separate online 
survey conducted reported practical factors, including cost and accessibility, as the 
primary reasons for transitioning from prescription opioids to heroin. In this context, it 
is of significance to investigate the trends in the retail price and availability of both illicit 
and prescription opioids. Specifically, we selected to look into opioid availability among 
people who inject drugs (PWID) as overdose remains a key risk among PWID with 30-
45% of PWID experiencing at least one non-fatal overdose in their lifetime (13-15); 
overdose, in turn, can lead to further morbidity including acute hypoxia and other end-
organ damage (16) and mortality due to fatal injury (17). Therefore, the objective of our 
study was to examine temporal trends and correlates of availability of illicit and 
prescription opioids among PWID with a history of opioid use in Vancouver between 
2010 and 2014.  
METHODS 
Study Procedure 
Data of this study were obtained from the At-Risk Youth Study (ARYS), the 
AIDS Care Cohort to evaluate Exposure to Survival Services (ACCESS), and the 
Vancouver Injection Drug Users Study (VIDUS). Details of these ongoing open 
prospective cohort studies have been described elsewhere (18). Briefly, VIDUS follows 
HIV-negative PWID and ACCESS follows HIV-positive people who use illicit drugs 
(other than or in addition to cannabis) (19, 20). ARYS enrolls street-involved youth aged 
14-26 years who use illicit drugs (other than or in addition to cannabis) (21). All 
participants had to reside in the Greater Vancouver region and provide informed 
consent at study enrollment. 
All studies utilized harmonized recruitment and data collection tools, allowing 
for combined analyses. All eligible participants were invited to complete an 
interviewer-administered questionnaire to obtain information regarding their 
sociodemographic characteristics, HIV risk behaviour, substance use patterns, and 
engagement with health and social services. Participants were followed up every 6 
months and were remunerated with $40 CAD for each visit. These studies have been 
approved by the University of British Columbia/Providence Health Care Research 
Ethics Board.   
Participants and Outcome Measure 
VIDUS, ACCESS and ARYS participants aged ≥18 years who had completed at 
least one study visit between June 1, 2010 and November 30, 2014, had ever injected 
drugs, had ever used heroin or prescription opioids by injection or non-injection, and 
had provided at least one valid answer to the questions about availability of five 
opioids at each visit were included in this study. The five categories for opioids 
included: (1) heroin; (2) Percocet (oxycodone/acetaminophen), Vicodin 
(hydrocodone/acetaminophen) or Demerol (meperidine); (3) Dilaudid 
(hydromorphone); (4) Morphine; (5) Oxycontin/OxyNEO (controlled-release 
oxycodone). The assessment of oxycontin availability was switched to OxyNEO after 
May 31, 2012 as oxycontin was removed from the British Columbia formulary in March 
2012. As in a previous study (8), substance availability was assessed based on the 
question “How difficult would it be for you to get the following drugs right now in the 
area where you typically obtain your drugs?” The responses were categorized at five 
levels: (1) within 10 minutes; (2) within 90 minutes; (3) within a day; (4) in more than a 
day; (5) could not access this drug. For the present analyses, the availability was 
dichotomized into two groups: immediate availability (within 10 minutes) and delayed 
(i.e., > 10 minutes) availability or not available. We focused on immediate availability as 
our sample had a history of injecting drug use and already had access to opioids. 
Explanatory Variables 
We selected explanatory variables that we hypothesized might affect the 
availability of illicit and prescribed opioids based on previous studies (8, 13, 22). In 
addition to sex (male vs. female), age (per 10 years increase), and ethnicity/ancestry 
(Caucasian vs. others), we considered the following social and structural exposures: 
homelessness; incarceration (held overnight in jail, prison or a penitentiary at least once 
within the past six months); drug dealing; and sex work within the past six months. We 
also included residence in Downtown Eastside (DTES), one of the largest open drug 
scenes in North America, within the past six months as proximity to this area may 
predict higher accessibility to opioids (21). Substance-using behaviors and outcomes in 
the past six months included at least daily injection of prescription opioids (OxyNEO, 
oxycontin, Percocet, Tylenol 3, morphine, Dilaudid, Demerol, methadone, fentanyl, 
Vicodin, or Talwin), heroin, cocaine, and methamphetamine, respectively, at least daily 
crack smoking, heavy alcohol use (as defined by the National Institute on Alcohol 
Abuse and Alcoholism: an average of >three drinks per occasion, or >seven drinks per 
week among females, and an average of >four drinks per occasion, or >14 drinks per 
week among males), and non-fatal overdose. Variables related to healthcare access 
during the past six months included: enrollment in methadone maintenance therapy 
(MMT), experiencing barriers to accessing healthcare such as not having a regular 
physician and discrimination for being on MMT (any vs. none), and having tried but 
unable to access addiction treatment services. A history of having ever been refused a 
pain medication was also included as a time-updated variable. Lastly, we included 
calendar year of interview (per year increase) and cohort designation (ACCESS vs. 
ARYS vs. VIDUS). All variables referring to behaviors and events during the past six 
months were treated as time-varying variables. 
Statistical Analysis 
To start, we examined the baseline sample characteristics stratified by availability 
of heroin and compared using the Pearson’s Chi-squared test for categorical variables 
and Wilcoxon Rank Sum test for continuous variables. To analyze factors that we 
hypothesized to be associated with accessibility to opioids obtained from serial data for 
each participants, we used univariable and multivariable generalized estimating 
equations (GEE) that adjusted for multiple observations per person using an 
exchangeable working correlation structure. We started with univariable GEE analyses 
to examine factors associated with the availability of each of the five groups of opioids. 
We included all explanatory variables associated with availability of opioids at the level 
of p < 0.10 in univariable analyses in an initial full multivariable model and used an a 
priori-defined backward model selection procedure based on examination of 
quasilikelihood under the independence model criterion statistic (QIC). Specifically, we 
examined the QIC of the model, removed the variable with the largest p-value, built a 
reduced model, and continued this iterative process until we obtained a multivariable 
model with the lowest QIC value.  
As a sub-analysis, we examined changes in the price of opioids during the study 
period. We presented the median and interquartile range of the price of each opioid for 
each calendar year. All statistical analyses were performed using SAS version 9.4 (SAS 
Institute, USA). All tests of significance were two sided, and a p < 0.05 was selected for 
defining statistical significance. 
RESULTS 
During the study period, 2228 participants completed at least one study visit. We 
excluded 644 (29%) participants who never injected drugs, never used heroin, or 
prescription opioids, or did not have at least one valid answer to the availability of the 
five groups of opioids at each visit. In total, 1584 participants were included in this 
study. Among them, 564 (35.6%) were female, 981 (61.9%) reported Caucasian ancestry, 
and the median age at baseline was 41.9 years (interquartile range (IQR) = 30.3-49.3). 
The median number of visit per participant during the study period was 5 (IQR = 2-8). 
As shown in Table 1, 98 (6.2%) and 333 (21.0%) participants reported at least daily 
prescription opioid injection and heroin injection use within the past six months at 
baseline, respectively.  
Figure 1 depicts changes in proportion of participants who reported immediate 
availability of each of the five groups of opioids investigated in this study. Between 
2010 and 2014, there were increases in the proportion reporting immediate availability 
of all the opioids except for oxycontin/OxyNEO. Of note, the proportion of participants 
reported immediate availability to heroin increased from 77.3% in 2010 to 87.4% in 2014.  
The results of the univariable and multivariable GEE analyses of factors 
associated with availability of the five groups of opioids are presented in Table 2 and 3. 
Calendar year of interview was independently and positively associated with 
immediate availability of all five groups of opioids (adjusted odds ratio [AOR] ranging 
from 1.09 for morphine and Dilaudid to 1.13 for Percocet/Vicodin/Demerol; all p < 
0.05) except for oxycontin/OxyNEO. DTES residence, recent involvement with drug 
dealing, and recent daily prescription opioid injection were independently and 
positively associated with immediate availability of all five groups of opioids (all p < 
0.05).  
At least daily heroin injection (AOR = 1.50, 95% confidence interval [CI]: 1.25-
1.79), daily cocaine injection (AOR = 1.69, 95% CI: 1.24-2.32) and daily crack smoking 
(AOR = 1.23, 95% CI: 1.03-1.47) were independently and positively associated with 
immediate availability of heroin, but not other opioids. Heavy alcohol use, on the other 
hand, was negatively associated with immediate availability of heroin (AOR = 0.80, 95% 
CI: 0.68-0.93). Enrollment in MMT was independently and positively associated with 
immediate availability of heroin (AOR = 1.34, 95% CI: 1.16-1.55). History of being 
refused pain medication was independently and positively associated with immediate 
availability of all opioids (p ≤ 0.05) except for heroin. Male sex was independently 
associated with immediate availability of Dilaudid only (AOR = 1.17, 95% CI: 1.02-1.34), 
and older age was independently and positively associated with immediate availability 
of Percocets/Vicodin/Demerol and OxyNEO/oxycontin (all p <0.05).  
In the sub-analysis, between 2010 and 2014, there was no change in the median 
price for all the opioids except for OxyNEO/oxycontin (Table 4), for which the median 
price had increased from $10 to $20 CAD per 40mg pill since 2010, and 
Percocets/Vicodin/Demerol, for which the median price had increased from $3 to $5 
CAD per pill. Otherwise, the price remained stable at a median of $10 CAD per pill. 
DISCUSSION 
Among these cohorts of PWID with history of opioid use in Vancouver, a 
significant increase in the immediate availability of illicit and prescription opioids 
(except for OxyNEO/oxycontin) was observed between 2010 and 2014. This increase 
persisted despite no significant change in their median prices of drugs, and even after 
accounting for potential confounders such as residence in drug scenes, engagement in 
drug dealing and high intensity opioid use. Male sex, older age, daily heroin or cocaine 
injection, daily crack smoking, enrollment in MMT, and history of being refused pain 
medications were independently and positively associated with immediate availability 
of some but not all formulations of illicit and prescription opioids.  
Our findings suggest that previously reported increasing trends of prescription 
opioids availability documented between 2006 and 2010 among street drug-using 
populations in this setting were continuing to rise through to 2014 (8). This continued 
increase in the availability of prescription opioids is particularly worrisome as multiple 
strategies to reduce prescription opioids access have been implemented, including 
increasing awareness and education to healthcare professionals, enforcing prescription 
surveillance, and implementing policies to counter opioid use and overdose over the 
last five years (23). However, a significant decrease in immediate availability of 
oxycontin/OxyNEO was observed between 2010 and 2014 in our study. The decrease 
was likely a result of the policy change regarding oxycontin and OxyNEO prescription. 
In 2012, oxycontin was removed and OxyNEO was restricted from the formulary in 
seven provinces in Canada, including British Columbia, and the provincial program 
covering the cost of these opioids was discontinued. OxyContin and OxyNEO were 
only prescribed to patients with chronic pain in situations where the physician 
requested Special Authority Approval for exceptional coverage supported with 
adequate rationale (24). The discontinuation of oxycontin and restriction of OxyNEO 
could contribute to the increasing demand in other illicit and prescription opioids, as 
previously hypothesized by Fischer & Keates (2012). The proposed rationale was that 
oxycontin and OxyNEO users resorted to using other prescription opioids such as 
hydromorphone and morphine as they had similar potency and potential for overuse 
(25, 26). At the same time of the discontinuation, an abuse-deterrent formulation of 
oxycontin, which was more difficult to crush or dissolve, was introduced to the market 
with intention to discourage use through injection or inhalation. The formulation was 
found to reduce the selection of oxycontin as the primary drug among a cohort of 
patients with opioid dependence who used prescription opioids as their primary drug 
from 35.6% to 12.8% after 21 months since the abuse-deterrent formulation was 
introduced (27). Sixty-six percent of the cohort reported switching to a different opioid, 
with heroin being the most common opioid people switched to as heroin was said to be 
easier to use, cheaper, and more readily available. This finding resonates with the 
increase in immediate heroin availability noted in our study. While our study cannot 
determine causation between the delisting of oxycontin and the increase in availability 
of other illicit and prescription opioids, it is certainly an area that necessitates further 
research.  
The observed increase in heroin availability in concurrence with the increase in 
prescription opioids availability is concerning from the public health perspective. 
Previous studies have suggested that heroin use patterns among PWID correspond with 
market availability of heroin – heroin users may reduce heroin use when supply is 
scarce, but actively seek heroin when it is available (28, 29). Therefore, the increasing 
availability of both heroin and prescription opioids may correspond with potentially 
increasing prevalence of PWID using both heroin and prescription opioids or 
transitioning back to heroin. Such trend is not benign as previous research had shown 
that PWID who use both heroin and prescription opioids and heroin alone may be at 
significantly higher risk of non-fatal overdose compared to PWID who uses prescription 
opioids alone (30). In view of the increasing trend in both heroin and prescription 
opioid availability, further research is necessary to clearly identify how prescription 
opioid use impacts heroin use among PWID.  
Participation in MMT was found to be independently associated with immediate 
availability of heroin. MMT is commonly used to treat opioid use disorder (31), and 
therefore, it is plausible that PWID on MMT had a history of high intensity heroin use 
and consequently retained social network or other characteristics associated with more 
immediate access to heroin. However, MMT patients also have a high prevalence (55-
61%) of concurrent chronic pain (32). Voon, Callon (33) found enrollment in MMT was 
associated with denial of analgesia and inadequate pain management. Among a cohort 
PWID enrolled in MMT in Vancouver between 2011 and 2014, 61.1% of them reported 
self-management of pain due to perception of inadequate analgesia secondary to under-
treatment of pain or opioid-induced hyperalgesia (34). Voon, Callon (35) had shown 
that patients who self-manage pain often did so via high-risk methods including 
injection of heroin and diverted opioids, which could explain the association between 
MMT enrollment and immediate availability to heroin. In contrast, we also find that 
those who have ever been denied pain medications were more likely to report 
immediate availability of all opioids except for heroin. Portenoy, Dole (36) found that 
patients with pain disorder and concurrent substance use disorder were less likely to 
receive adequate pain management due to various reasons such as difficulty in 
distinguishing pain from drug seeking behavior and tolerance. This may suggest that 
PWID with pain disorder were resorting to use of prescription opioids from street 
markets to attain sufficient pain management.  
Our study also found that those who engaged in heavy alcohol use were less 
likely to report immediate availability of heroin. Few studies have analyzed the 
association between opioids and alcohol use. Anglin, Almog (37) and Hser, Anglin (38) 
both found an inverse relationship between alcohol consumption and heroin use among 
a cohort of heroin users. This could be due to the substitution effect of the two 
substances both being central nervous system depressants and prevalence of media 
highlighting the danger of mixing the two substances (39, 40). In addition, previous 
research had shown a reduction in alcohol intake among opioid users enrolled in MMT 
(41). However, more recent studies had shown a high concurrence of alcohol and opioid 
use, estimated at between 35-47%, in PWID enrolled in MMT (42-44). A systemic review 
by Srivastava, Kahan (45) revealed no clear pattern between alcohol use and MMT 
among people with opioid dependence as fifteen studies reviewed concluded 
inconsistent patterns of alcohol use. The relationship between alcohol and opioid use is 
inconclusive but is an area that requires further research as it has clinical implications 
regarding prognosis and adherence to opioid use disorder treatment.   
Our study is not without limitations. First, VIDUS, ARYS and ACCESS were not 
randomly sampled from PWID in Vancouver and therefore it is unclear to what extent 
the results of this study can be generalized. Second, as an observational study, our 
study is subjected to unmeasured confounders that may have impacted the true 
temporal trends or correlates of availability of each of the opioids assessed in this study. 
Third, the data was obtained from self-report of the participants and may be subjected 
to reporting bias. Lastly, this study does not account for fluctuating drug purity which 
may affect the availability of the substances.  
In conclusion, the present study demonstrated an increasing immediate 
availability of heroin in concurrence with prescription opioids (morphine, Dilaudid and 
Percocet/Vicodin/Demerol) among opioid users in Vancouver between 2010 and 2014, 
which persisted after extensive adjustment for potential confounders. The increasing 
availability of heroin along with prescription opioids is particularly worrisome given 
the recent shift in opioid use pattern. Further research is needed to determine how 
prescription opioid use affect heroin use and how availability of both illicit and 
prescription opioids affect the opioid use patterns among PWID.  
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Table 1: Baseline characteristics of 1584 Opioid Users in Vancouver, Canada, 2010–2014. 
Characteristic 
Total 
n (%) 
Heroin 
immediate 
availability 
n=1199 (75.7%) 
Heroin delayed 
availability or not 
available  
N=384 (24.2%) 
P - value 
Sex (male) 1020 (64.4) 770 (64.2) 249 (64.8) 0.824 
Age (median [IQR]) 41.9 
(30.3-49.3) 
41.9 
(30.3-49.0) 
41.6 
(30.4-50.5) 
0.525 
Caucasian 981 (61.9) 748 (62.4) 232 (60.4) 0.489 
Homelessnessa 473 (29.9) 379 (31.6) 94 (24.5) 0.008 
Live in DTESa 919 (58.0) 779 (65.0) 140 (36.5) <0.001 
Involved in Drug Dealinga 408 (25.8) 358 (29.9) 50 (13.0) <0.001 
Involved in Sex Worka 176 (11.1) 148 (12.3) 28 (7.3) 0.006 
≥ Daily PO Injection Drug Usea 98 (6.2) 86 (7.2) 11 (2.9) 0.002 
≥ Daily Heroin Injection Usea 333 (21.0) 285 (23.8) 48 (12.5) <0.001 
≥ Daily Cocaine Injection Usea 87 (5.5) 81 (6.8) 6 (1.6) <0.001 
≥ Daily Meth Injection Usea 103 (6.5) 83 (6.9) 20 (5.2) 0.241 
≥ Daily Crack Smokinga 359 (22.7) 300 (25.0) 59 (15.4) <0.001 
Heavy Alcohol Usea 259 (16.4) 182 (15.2) 77 (20.1) 0.026 
Overdosea 127 (8.0) 100 (8.3) 27 (7.0) 0.411 
Participated in MMTa 812 (51.3) 644 (53.7) 168 (43.8) <0.001 
Unable to Access Addiction Treatmenta 131 (8.3) 100 (8.3) 31 (8.1) 0.879 
Barrier to Access Healthcarea 354 (22.3) 266 (22.2) 88 (22.9) 0.765 
Ever Refused Pain Medications 484 (30.6) 367 (30.6) 116 (30.2) 0.754 
Incarcerationa 166 (10.5) 139 (11.6) 27 (7.0) 0.011 
 Cohort Designation:     
ACCESS 515 (32.5) 389 (32.4) 125 (32.6) 0.613 
ARYS 294 (18.6) 214 (17.9) 80 (20.8) 0.161 
VIDUS 775 (48.9) 596 (49.7) 179 (46.6) ref 
DTES, Downtown East Side; PO, Prescription Opioids; IQR, interquartile range; MMT, methadone maintenance therapy; PO, 
prescription opioid.  ACCESS: AIDS Care Cohort to evaluate Exposure to Survival Services. VIDUS: Vancouver Injection Drug 
Users Study. ARYS (At-Risk Youth Study). 
a denotes activities/events in the past 6 months. 
 Table 2: Univariable and multivariable GEE analyses of factors associated with more immediate availability (within 10 minutes) 
to heroin, Percocets/Vicodin/Demerol, and Dilaudid among opioid users in Vancouver, Canada (n=1584). 
 
 
 
Characteristic 
Heroin Percocets/Vicodin/Demerol Dilaudid 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Calendar Year of Interview 
(Per year later) 
1.08 (1.04-1.12) 1.12 (1.07 –1.16) 1.12 (1.08 - 1.15) 1.13 (1.09 – 1.17) 1.07 (1.04 - 1.11) 
 
1.09 (1.05 – 1.12) 
Sex 
     (Male vs. female)  
1.03 (0.87 - 1.22)  1.14 (0.99 - 1.30)  1.14 (1.00 - 1.31) 1.17 (1.02 – 1.34) 
Age 
     (Per 10 year increase)  
1.11 (1.03 - 1.19)  1.29 (1.22 - 1.37) 1.11 (1.03 – 1.19) 1.22 (1.15 - 1.29)  
Ancestry 
     (Caucasian vs. others) 
0.95 (0.81 - 1.12)  0.95 (0.83 - 1.08)  1.00 (0.88 - 1.14)  
Homelessnessa 
     (Yes vs. no) 
1.22 (1.05 - 1.41)  0.93 (0.82 - 1.04)  0.97 (0.86 - 1.10)  
DTES residencea 
     (Yes vs. no)  
2.46 (2.14 - 2.84) 2.26 (1.96 – 2.60) 1.88 (1.68 - 2.10) 1.82 (1.62 – 2.04) 2.00 (1.79 - 2.23) 1.93 (1.72 – 2.17) 
Drug Dealinga 
     (Yes vs. no) 
1.70 (1.47 - 1.96) 1.53 (1.30 – 1.79) 1.25 (1.11 - 1.40) 1.28 (1.12 – 1.45) 1.27 (1.13 - 1.43) 1.25 (1.10 – 1.41) 
Sex Worka 
     (Yes vs. no)  
1.45 (1.15 - 1.83)  1.05 (0.87 - 1.25)  1.08 (0.91 - 1.29)  
PO injectiona 
     (≥daily vs. <daily) 
1.46 (1.11 - 1.92) 1.48 (1.10 – 1.99) 1.41 (1.15 - 1.74) 1.41 (1.14 – 1.74) 1.75 (1.39 - 2.21) 1.80 (1.41 – 2.30) 
Heroin injectiona 
     (≥daily vs. <daily) 
1.69 (1.45 - 1.97) 1.50 (1.25 – 1.79) 1.12 (0.99 - 1.27)  1.17 (1.03 - 1.32) 1.09 (0.96 – 1.25) 
Cocaine injectiona 
     (≥daily vs. <daily) 
2.04 (1.56 - 2.67) 1.69 (1.24 – 2.32) 1.41 (1.16 - 1.72) 1.20 (0.97 – 1.48) 1.41 (1.17 - 1.71) 1.19 (0.97 – 1.46) 
Meth injectiona 
     (≥daily vs. <daily) 
1.27 (1.00 - 1.62)  1.05 (0.86 - 1.28)  1.09 (0.90 - 1.31)  
 
 
 
Crack smokinga 
     (≥daily vs. <daily) 
1.49 (1.28 - 1.74) 1.23 (1.03 – 1.47) 1.13 (0.99 - 1.28)  1.10 (0.98 - 1.25)  
Heavy alcohol usea 
     (Yes vs. no)  
0.80 (0.68 - 0.93) 0.80 (0.68 – 0.93) 0.99 (0.87 - 1.13)  0.97 (0.85 - 1.11)  
Overdosea 
     (Yes vs. no)  
0.95 (0.77 - 1.16)  0.88 (0.75 - 1.03)  1.01 (0.86 - 1.19)  
Participated in MMTa 
     (Yes vs. no) 
1.36 (1.19 - 1.55) 1.34 (1.16 – 1.55) 1.19 (1.06 - 1.33)  1.18 (1.05 - 1.32) 1.12 (0.99 – 1.26) 
Unable to access addiction 
treatmenta 
     (Yes vs. no)  
0.95 (0.76 - 1.18)  0.81 (0.66 - 1.00)  0.89 (0.72 - 1.09)  
Barrier to healthcarea 
     (Any vs. none)  
0.91 (0.79 - 1.04)  0.91 (0.81 - 1.03)  0.96 (0.86 - 1.08)  
Ever refused pain 
medicationsb 
     (Yes vs. no)  
1.22 (1.06 - 1.40)  1.37 (1.22 - 1.54) 1.13 (1.01 – 1.27) 1.36 (1.21 - 1.53) 1.19 (1.05 – 1.34) 
Incarcerationa 
     (Yes vs. no)  
1.17 (0.96 - 1.43)  0.89 (0.75 - 1.06)  0.99 (0.83 - 1.18)  
Cohort designation:       
(ACCESS vs. VIDUS) 0.92 (0.77 - 1.10) 0.96 (0.81 – 1.14) 1.01 (0.88 - 1.16) 1.04 (0.90 – 1.19) 0.99 (0.86 - 1.14) 1.03 (0.90 – 1.19) 
(ARYS vs. VIDUS) 0.55 (0.44 - 0.69) 0.65 (0.51 – 0.82) 0.42 (0.34 - 0.51) 0.56 (0.43 – 0.72) 0.48 (0.40 - 0.59) 0.54 (0.44 – 0.67) 
GEE: generalized estimating equations. OR: odds ratio. CI: confidence interval. DTES: Downtown Eastside. PO: prescribed opioids. MMT: 
methadone maintenance therapy. ACCESS: AIDS Care Cohort to evaluate Exposure to Survival Services. VIDUS: Vancouver Injection Drug Users 
Study. ARYS (At-Risk Youth Study). 
a Denotes activities in the previous six months.  
b Time-updated. 
 Table 3: Univariable and multivariable GEE analyses of factors associated with more immediate availability (within 10 minutes) 
to morphine and oxycontin/OxyNEO among opioid users in Vancouver, Canada (n=1584). 
 
 
 
Characteristic 
Morphine Oxycontin/OxyNEO 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Calendar Year of Interview 
(Per year later) 
1.07 (1.04 - 1.11) 1.09 (1.05 – 1.12) 0.95 (0.92 - 0.98) 0.96 (0.93 – 0.99) 
Sex 
     (Male vs. female)  
1.10 (0.96 - 1.26)  1.09 (0.96 - 1.24)  
Age 
     (Per 10 year increase)  
1.23 (1.16 - 1.30)  1.17 (1.11 - 1.24) 1.08 (1.00 – 1.16) 
Ancestry 
     (Caucasian vs. others) 
0.98 (0.86 - 1.12)  0.97 (0.86 - 1.10)  
Homelessnessa 
     (Yes vs. no) 
0.99 (0.89 - 1.12)  1.02 (0.90 - 1.15)  
DTES residencea 
     (Yes vs. no)  
2.08 (1.87 - 2.32) 2.03 (1.81 – 2.27) 1.90 (1.71 - 2.11) 1.79 (1.61 – 2.00) 
Drug Dealinga 
     (Yes vs. no) 
1.24 (1.10 - 1.40) 1.23 (1.09 – 1.39) 1.23 (1.09 - 1.39) 1.24 (1.09 – 1.40) 
Sex Worka 
     (Yes vs. no)  
1.10 (0.92 - 1.31)  1.13 (0.95 - 1.34)  
PO injectiona 
     (≥daily vs. <daily) 
1.70 (1.35 - 2.14) 1.78 (1.40 – 2.27) 1.46 (1.16 - 1.84) 1.39 (1.11 – 1.75) 
Heroin injectiona 
     (≥daily vs. <daily) 
1.16 (1.03 - 1.31)  1.10 (0.97 - 1.25)  
Cocaine injectiona 
     (≥daily vs. <daily) 
1.40 (1.15 - 1.71) 1.20 (0.97 – 1.47) 1.42 (1.16 - 1.74) 1.22 (0.99 – 1.51) 
Meth injectiona 
     (≥daily vs. <daily) 
1.14 (0.94 - 1.38)  1.04 (0.85 - 1.26)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crack smokinga 
     (≥daily vs. <daily) 
1.14 (1.00 - 1.29)  1.19 (1.04 - 1.35) 
 
Heavy alcohol usea 
     (Yes vs. no)  
1.00 (0.87 - 1.14)  1.01 (0.88 - 1.17) 
 
Overdosea 
     (Yes vs. no)  
0.96 (0.81 - 1.13)  0.82 (0.68 - 0.99) 0.86 (0.70 – 1.05) 
Participated in MMTa 
     (Yes vs. no) 
1.18 (1.05 - 1.32) 1.09 (0.97 – 1.22) 1.11 (0.99 - 1.24)  
Unable to access addiction 
treatmenta 
     (Yes vs. no)  
0.88 (0.72 - 1.07)  0.93 (0.75 - 1.15)  
Barrier to healthcarea 
     (Any vs. none)  
0.96 (0.86 - 1.08)  0.87 (0.77 - 0.98) 0.90 (0.79 – 1.01) 
Ever refused pain medicationsb 
     (Yes vs. no)  
1.39 (1.24 - 1.57) 1.22 (1.08 – 1.37) 1.18 (1.05 - 1.32) 1.12 (1.00 – 1.26) 
Incarcerationa 
     (Yes vs. no)  
1.03 (0.87 - 1.22)  0.93 (0.78 - 1.11) 
 
Cohort designation:     
(ACCESS vs. VIDUS) 1.04 (0.91 - 1.20) 1.08 (0.94 – 1.24) 1.05 (0.92 - 1.19) 1.07 (0.94 – 1.22) 
(ARYS vs. VIDUS) 0.47 (0.39 - 0.58) 0.54 (0.44 – 0.67) 0.53 (0.43 - 0.65) 0.75 (0.58 – 0.98) 
GEE: generalized estimating equations. OR: odds ratio. CI: confidence interval. DTES: Downtown Eastside. PO: prescribed opioids. MMT: 
methadone maintenance therapy. ACCESS: AIDS Care Cohort to evaluate Exposure to Survival Services. VIDUS: Vancouver Injection Drug Users 
Study. ARYS (At-Risk Youth Study). 
a Denotes activities in the previous six months.  
b Time-updated. 
 
Figure 1. Proportion of ever-users of opioids in Vancouver, Canada indicating immediate availability (scoring within ≤10 minutes) 
from 2010-2014, n=1584 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Median retail price and unit of five groups of opioid between 2010 and 2014 reported by opioid users in Vancouver, 
Canada 
Substance Year Median Price and Unit Interquartile Range 
Heroin 2010  10 CAD/half point 10 - 10 
 2011  10 CAD/half point 10 - 10 
 2012  10 CAD/half point 10 - 10 
 2013  10 CAD/half point 10 - 10 
 2014  10 CAD/half point 10 - 10 
Percocet/Vicodin/Demerol 2010  3 CAD/pill 3 - 5 
 2011  4 CAD/pill 3 - 5 
 2012  4 CAD/pill 3 - 5 
 2013  5 CAD/pill 3 - 5 
 2014  5 CAD/pill 3 - 5 
Dilaudid 2010  10 CAD/8mg pill 10 - 10 
 2011  10 CAD/8mg pill 10 - 10 
 2012  10 CAD/8mg pill 10 - 10 
 2013  10 CAD/8mg pill 10 - 10 
 2014  10 CAD/8mg pill 10 - 10 
Morphine 2010  10 CAD/100mg pill 10 - 10 
 2011  10 CAD/100mg pill 10 - 10 
 2012 10 CAD/100mg pill 10 - 10 
 2013  10 CAD/100mg pill 10 - 10 
 2014  10 CAD/100mg pill 10 - 10 
Oxycontin 2010  10 CAD/40mg pill 10 - 20 
Oxycontin 2011  20 CAD/40mg pill 10 - 20 
Oxycontin/OxyNEO 2012  20 CAD/40mg pill of oxycontin or 25mg 
pill of OxyNEO 
10 - 20 
OxyNEO 2013  20 CAD/25mg pill 10 - 20 
OxyNEO 2014  20 CAD/25mg pill 10 - 20 
 
